National Comprehensive Cancer Network

About NCCN

NCCN Guidelines and Compendium Updated

Flash Update sent September 12, 2012

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Breast Cancer. These NCCN Guidelines® are currently available as Version 3.2012.

  • (BINV-20) Footnote "uu" was added for the consideration of pertuzumab therapy as a second-line option for patients with disease progression after trastuzumab-based therapy. The footnote states: "Patients previously treated with chemotherapy plus trastuzumab in the absence of pertuzumab may be considered for one line of therapy including both trastuzumab plus pertuzumab in combination with or without cytotoxic therapy (such as vinorelbine or taxane). Further research is needed to determine the ideal sequencing strategy for anti-HER2 therapy."
  • The Discussion section has been updated to reflect the changes in the algorithm.

*For your reference, the announcement of the previous update (Version 2.2012) to the NCCN Guidelines for Breast Cancer, distributed on July 12, 2012 is included below:

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Breast Cancer. These NCCN Guidelines® are currently available as Version 2.2012.

  • Pertuzumab in combination with trastuzumab and a taxane is included as a preferred first-line option for human epidermal growth factor receptor 2 (HER2)-positive recurrent or metastatic breast cancer that is hormone receptor-negative or hormone receptor-positive and endocrine therapy refractory. The regimen containing pertuzumab and trastuzumab in combination with docetaxel is category 1 and pertuzumab and trastuzumab in combination with paclitaxel is category 2A.
  • The Discussion section has been updated to reflect the changes in the algorithm.

 

For the complete updated version of these and all NCCN Guidelines, visit NCCN.org.